Make Sure Patients on Sublocade Have an Active Order in the EHR

March 2018

Sublocade (SUB-loh-kayd) will be the first monthly buprenorphine injection for patients with opioid use disorder.

It's a subcutaneous depot injection given in the abdomen for patients stable on 8 to 24 mg/day of buccal or sublingual buprenorphine.

But it's different from Probuphine, the 6-month implant that's only for patients on up to 8 mg/day of buprenorphine.

Get concise advice on drug therapy, plus unlimited access to CE

Hospital Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote